Astellas’ XOSPATA Fails Phase III Primary Endpoint in Frontline AML – FLT3 Inhibitor Misses OS Benefit vs. Midostaurin

Astellas Pharma Inc. (TYO: 4503) and the HOVON Foundation announced that the Phase III HOVON 156 / AMLSG 28-18 / PASHA study of XOSPATA (gilteritinib) failed to meet its primary endpoint of overall survival (OS) in newly diagnosed FLT3-mutation-positive (FLT3m+) acute myeloid leukemia (AML). While the study did not demonstrate superior OS versus the midostaurin-based regimen, gilteritinib showed comparable survival benefit with similar safety profiles, preserving its relapsed/refractory (R/R) positioning but limiting frontline expansion potential for the $400M+ revenue franchise.

Clinical Trial Results

Study Design:

• Name: HOVON 156 / AMLSG 28-18 / PASHA
• Phase: III
• Comparator: Midostaurin (first-generation FLT3 inhibitor) + intensive chemotherapy
• Sponsors: Astellas Pharma + HOVON Foundation (Dutch cooperative group)

Drug Profile & Approved Indications

Strategic Implications

Competitive Landscape

Forward-Looking Considerations

• Combination Strategies: XOSPATA + venetoclax + azacitidine (non-intensive) studies ongoing for unfit patients
• MRD-Driven Trials: Exploratory endpoints may support adjuvant or maintenance positioning post-remission
• Quizartinib Threat: If QuANTUM-First succeeds, XOSPATA R/R share at risk due to physician familiarity with competitor
• Generic Timeline: Midostaurin patent expiry 2027 may open frontline market for cost-effective alternatives

Forward‑Looking Statements
This brief contains forward‑looking statements regarding XOSPATA’s commercial trajectory, competitive positioning, and pipeline adjustments following the Phase III failure. Actual results may differ due to competitive dynamics with quizartinib, combination study outcomes, and pricing pressures in the R/R AML market.-Fineline Info & Tech